CUPR
Cuprina Holdings (Cayman) Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$1.87
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 63.2K | 49.9K | 48.3K | 100.8K | 56.6K |
| Cost of Revenue | 79.9K | 50.5K | 51.3K | 64.2K | 36.6K |
| Gross Profit | (16.6K) | (645.00) | (3.0K) | 36.6K | 20.0K |
| Operating Expenses | |||||
| R&D Expense | 278.1K | 226.9K | 241.4K | 167.7K | 292.9K |
| SG&A Expense | 5.9M | 4.4M | 1.3M | 833.4K | 830.4K |
| General & Admin Expense | — | 4.4M | 1.3M | 826.7K | 790.6K |
| Selling & Marketing Expense | — | 7.9K | 6.5K | 6.7K | 39.7K |
| Other Expenses | — | (54.5K) | 131.6K | 103.8K | 72.5K |
| Total Operating Expenses | 6.2M | 4.6M | 1.6M | 1.1M | 1.2M |
| Cost and Expenses | 6.3M | 4.6M | 1.7M | 1.2M | 1.2M |
| Operating Income (EBIT) | (6.2M) | (4.6M) | (1.6M) | (1.1M) | (1.2M) |
| Non-Operating | |||||
| Interest Income | 26.5K | 26.6K | — | — | — |
| Interest Expense | 7.0K | 14.7K | 37.2K | 56.6K | 2.0K |
| Net Interest Income | 21.6K | 11.8K | (37.2K) | (56.6K) | (2.0K) |
| Other Non-Op Income/Expense | 227.0K | (105.8K) | 136.7K | (17.4K) | 88.6K |
| Non-Operating Income (excl Interest) | — | 27.8K | (173.9K) | (39.1K) | (90.6K) |
| EBT (Pre-Tax Income) | (6.0M) | (4.7M) | (1.5M) | (1.1M) | (1.1M) |
| Income Tax Expense | — | — | 51.9K | 33.8K | 7.3K |
| Bottom Line | |||||
| Net Income | (6.0M) | (4.7M) | (1.6M) | (1.1M) | (1.1M) |
| Earnings from Cont. Ops | (6.0M) | (4.7M) | (1.6M) | (1.1M) | (1.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.0M) | (4.7M) | (1.6M) | (1.1M) | (1.1M) |
| Per Share | |||||
| Basic EPS | ($2.32) | ($1.84) | ($0.57) | ($0.41) | ($0.43) |
| Diluted EPS | ($2.32) | ($1.84) | ($0.57) | ($0.41) | ($0.43) |
| Revenue Per Share | $0.02 | $0.02 | $0.02 | $0.04 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 2.7M | 2.6M | 2.7M | 2.7M | 2.6M |
| Diluted Shares Outstanding | 2.7M | 2.6M | 2.7M | 2.7M | 2.6M |
| Profitability Metrics | |||||
| EBITDA | (6.2M) | (4.6M) | (1.4M) | (994.1K) | (1.1M) |
| D&A | 46.7K | 36.5K | 42.2K | 35.1K | 29.1K |
| EBIT | (6.2M) | (4.6M) | (1.5M) | (1.0M) | (1.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025